Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Funding
TumorGen Receives $390K NCI Grant to Counter Metastasis
Details : With this funding, the company will test the new technology in lung cancer patients, capturing metastatic cancer cell clusters (MCCCs) in their blood.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?